Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis | Zendy

Paul Hodgkins | Zendy; Linnette Yen | Zendy; Aaron Yarlas | Zendy; Robyn G. Karlstadt | Zendy; Dory Solomon | Zendy; Sunanda V. Kane | Zendy

Open Access

Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis

Author(s) -

Paul Hodgkins,

Linnette Yen,

Aaron Yarlas,

Robyn G. Karlstadt,

Dory Solomon,

Sunanda V. Kane

Publication year - 2012

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1002/ibd.23022

Subject(s) - mmx , medicine , ulcerative colitis , quality of life (healthcare) , disease burden , disease , burden of disease , physical therapy , gastroenterology , nursing , computer science , operating system

Ulcerative colitis (UC) substantially reduces patients' health-related quality of life (HRQoL). The current study examined the burden of disease and the impact of daily multimatrix (MMX®) mesalamine treatment on HRQoL for patients with active or quiescent mild-to-moderate UC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research